Avid­i­ty touts ear­ly da­ta, show­ing pos­i­tive ef­fect on pro­gres­sive mus­cu­lar dis­ease while un­der par­tial FDA hold

An RNA biotech is look­ing to tout Phase I/II da­ta as in­vestors sent its share price on a re­bound.

Avid­i­ty Bio­sciences said Wednes­day that its can­di­date, AOC 1001, suc­cess­ful­ly tar­get­ed siR­NA to mus­cle in a bid to ad­dress the root cause be­hind a dis­ease known as my­oton­ic dy­s­tro­phy type 1, or DM1. The dis­ease, a ge­net­ic dis­or­der that caus­es pro­gres­sive mus­cle weak­ness, af­fects more than 40,000 peo­ple in the US, where there is no ap­proved ther­a­py.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER